Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | P2RX4 | Q99571 | 13/20 | 0.54 |
| ▸ | ALOX5 | P09917 | 1/20 | 0.39 |
| ▸ | MAOA | P21397 | 1/20 | 0.39 |
| ▸ | MAOB | P27338 | 1/20 | 0.39 |
| ▸ | AHR | P35869 | 1/20 | 0.38 |
| ▸ | P2RX1 | P51575 | 2/20 | 0.38 |
| ▸ | P2RX3 | P56373 | 1/20 | 0.38 |
| ▸ | MAPT | P10636 | 1/20 | 0.38 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.38 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.38 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL10586348 | 0.74 | P2RX4 (0.48) | P2RX4ALOX5MAOAMAOBP2RX1 | |
| SCHEMBL47007 | 0.74 | KDM4E (0.55) | P2RX4MAOAP2RX1MAPTSMN1; SMN2 | |
| SCHEMBL19175897 | 0.74 | P2RX4 (0.48) | P2RX4ALOX5MAOAMAOBP2RX1 | |
| SCHEMBL31191643 | 0.74 | P2RX4 (0.48) | P2RX4ALOX5MAOAMAOBAHR | |
| SCHEMBL13150242 | 0.74 | P2RX4 (0.48) | P2RX4ALOX5MAOAMAOBP2RX1 | |
| SCHEMBL20308266 | 0.74 | P2RX4 (0.48) | P2RX4ALOX5MAOAMAOBP2RX1 | |
| SCHEMBL31067286 | 0.74 | KDM4E (0.55) | P2RX4MAOAP2RX1MAPTSMN1; SMN2 | |
| SCHEMBL3974908 | 0.74 | P2RX4 (0.48) | P2RX4ALOX5MAOAMAOBP2RX1 | |
| SCHEMBL1423685 | 0.72 | P2RX4 (0.47) | P2RX4ALOX5MAOAMAOBP2RX1 | |
| SCHEMBL6123819 | 0.72 | P2RX4 (0.47) | P2RX4ALOX5MAOAMAOBP2RX1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8304539-B2 | Fused heteroaryl modulators of glucocorticoid receptor, AP-1, and/or NF-κB activity and use thereof | BRISTOL-MYERS SQUIBB COMPANY (US) | 2012-11-06 | — | — | US | disclosed |
| US-20110002952-A1 | FUSED HETEROARYL MODULATORS OF GLUCOCORTICOID RECEPTOR, AP-1, AND/OR NF-kappaB ACTIVITY AND USE THEREOF | BRISTOL-MYERS SQUIBB COMPANY | 2011-01-06 | — | — | US | disclosed |
| EP-2247597-A1 | FUSED HETEROARYL MODULATORS OF GLUCOCORTICOID RECEPTOR, AP-1, AND/OR NF-KB ACTIVITY AND USE THEREOF | Bristol-Myers Squibb Company (US) | 2010-11-10 | — | — | EP | disclosed |
| WO-2009100171-A1 | FUSED HETEROARYL MODULATORS OF GLUCOCORTICOID RECEPTOR, AP-1, AND/OR NF-KB ACTIVITY AND USE THEREOF | BRISTOL-MYERS SQUIBB COMPANY (US) | 2009-08-13 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20110002952-A1 | FUSED HETEROARYL MODULATORS OF GLUCOCORTICOID RECEPTOR, AP-1, AND/OR NF-kappaB ACTIVITY AND USE THEREOF | NFKB2, NFKBIA, AP1G1 | P2RX4 3591/4885ALOX5 799/4885MAOA 2890/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.